Bodyline Reaction: Should the government offer weight loss jabs to the unemployed?

Posted on October 18, 2024 by Sally-Anne Turner

On the 15th October 2024, the UK health secretary wrote an opinion piece in the Telegraph stating that the government should be providing the revolutionary weight loss jabs Mounjaro, which contains tirzepatide, or Wegovy, which contains semaglutide, to unemployed Brits with obesity to get them back to work. This announcement sparked considerable debate across the healthcare sector, political arena, and among the general public, raising important questions about how we approach obesity treatment, workplace health, and the allocation of NHS resources in the United Kingdom.

This opinion was met with support from the Prime Minister, Sir Keir Starmer, who said the life-changing drugs could be very important for public health and for the economy. The prime minister's endorsement of this approach signals a potential shift in how government policy addresses the intersection of health, employment, and economic productivity. However, this statement also raises fundamental questions about the purpose of healthcare provision, the role of employment status in determining access to treatment, and whether we're addressing the root causes of both obesity and unemployment in our society.

But how would this scheme work, and is it as beneficial as the government are making it out to be? The proposal, while well-intentioned, appears to oversimplify the complex relationship between obesity, employment, and overall health. The suggestion that providing weight loss medications to unemployed individuals will automatically result in increased workforce participation overlooks numerous factors, including the multifaceted nature of unemployment, the chronic nature of obesity as a disease, and the comprehensive support systems required for successful long-term weight management.

Here at Bodyline, we've been considering what this would mean for the country and the fight against the chronic disease obesity. This is not as simple an issue as it has been made out to be, and many factors must be considered in conversations like these. With nearly two decades of experience in medical weight loss treatment and having supported over 100,000 patients across the UK, we have witnessed firsthand the complexities involved in successful, sustainable weight management. Our expertise in this field allows us to offer a nuanced perspective on what such a government initiative would truly require to be effective.

These factors include the major upfront cost to the economy and NHS, the imbalance of care depending on socio-economic backgrounds as opposed to genuine need, the lifelong support required for medical weight loss treatment such as these, and the underlying issues in weight-related workplace discrimination. Additionally, we must consider the infrastructure required to deliver such a programme, the training needed for healthcare professionals, the monitoring systems necessary to ensure patient safety, and the long-term sustainability of funding for what would essentially be a lifelong treatment for many individuals.

Overall, at Bodyline we believe there needs to be a holistic approach and widespread change to the way obesity is viewed, treated, and considered – and medical weight loss injections are just one part of that. Our experience has shown us that successful weight management requires a comprehensive approach that addresses not just the physiological aspects of obesity but also the psychological, social, and environmental factors that contribute to weight gain and make weight loss challenging. Simply prescribing medication without this wraparound support is unlikely to produce the sustainable results that both individuals and the government are hoping to achieve.

How does obesity impact employment?

Obesity is, and should continue to be considered as, a significant concern in the workplace that impacts both employees and employers. The relationship between obesity and employment is bidirectional and complex, with obesity potentially affecting a person's ability to work, whilst certain working conditions and employment circumstances can contribute to the development and maintenance of obesity. Understanding this relationship is crucial when considering policy interventions that aim to address both issues simultaneously.

Living with obesity increases the risk of a number of serious health complications. These include heart disease, diabetes, and certain cancer types. In fact, obesity carries a higher risk of cancer than smoking, contributing to almost 8% of all cancer cases. Beyond these life-threatening conditions, obesity is associated with numerous other health issues including osteoarthritis, sleep apnoea, fatty liver disease, reproductive health problems, and mental health conditions such as depression and anxiety. Each of these conditions can independently affect a person's ability to work effectively, attend work regularly, and maintain employment long-term.

Over a quarter of UK adults are currently living with obesity, and numbers are rising across the world – it's expected the long-term health effects of chronic obesity will have a huge impact on our workforce. For this reason, Bodyline is pleased that we can spotlight on this topic thanks to the words of the health secretary. The conversation around obesity and employment is long overdue, and we welcome any initiative that recognizes obesity as a serious health condition requiring medical intervention. However, we believe the conversation must be broadened beyond just the unemployed to include all individuals living with obesity who could benefit from medical support.

It isn't clear if those already out of work are out of work because of their obesity – that is what the University of Manchester's trial, funded by pharmaceutical manufacturer Eli Lilly, will hope to find out. This research will be crucial in understanding whether there is a direct causal relationship between obesity and unemployment, or whether both are symptoms of other underlying issues such as socioeconomic disadvantage, lack of access to healthcare, mental health challenges, or disability. Without this evidence base, policies targeting unemployed individuals specifically may miss the mark entirely.

However, what is clear is that a very large proportion of UK society do struggle with their weight and subsequent weight health – whether they're in a job or not. The prevalence of obesity spans all employment categories, from those in full-time work to part-time employees, self-employed individuals, and those who are economically inactive for various reasons. This widespread nature of the condition suggests that any effective intervention needs to be accessible based on clinical need rather than employment status. At Bodyline Medical Wellness Clinics, we treat patients from all walks of life and employment situations, and we have not observed that unemployment is the primary factor determining who needs or will benefit from weight loss treatment.

The impact of obesity on employment manifests in several ways. Individuals with obesity may experience physical limitations that make certain types of work challenging or impossible. Jobs requiring physical stamina, mobility, or fitting into confined spaces may become inaccessible. Additionally, the health complications associated with obesity often result in increased sick leave, medical appointments, and periods of reduced productivity. Research suggests that employees with obesity take more sick days on average than their colleagues without obesity, contributing to the economic burden on employers and the wider economy.

Furthermore, there is substantial evidence of weight-based discrimination in the workplace. Studies have shown that individuals with obesity face bias in hiring decisions, receive lower starting salaries, are passed over for promotions, and are more likely to face disciplinary action or dismissal compared to their peers without obesity. This discrimination exists despite obesity being recognised as a disability in certain legal contexts. The stigma associated with obesity in professional settings can also affect an individual's confidence, mental health, and career progression, creating barriers to employment that medication alone cannot address.

What is Mounjaro or Tirzepatide?

It would be helpful to answer the question of what these weight loss medications are and why they are being dubbed the 'king of kong' of weight loss injections. Understanding the mechanism of action, clinical evidence, and practical considerations of these medications is essential for anyone considering whether this government proposal makes sense from a medical and practical standpoint.

Mounjaro is a medical weight loss injectable therapy that contains the active ingredient tirzepatide. This medication represents a significant advancement in the pharmaceutical treatment of obesity, building upon the success of earlier GLP-1 medications but adding an additional mechanism of action that appears to enhance weight loss results. Mounjaro is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm, making it relatively convenient for patients to self-administer at home once they have received appropriate training.

Tirzepatide mimics the effects of two hormones that are naturally produced in the body; these are glucose-dependent insulinotropic polypeptides (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. This dual-action mechanism is what sets Mounjaro apart from earlier weight loss medications that only targeted the GLP-1 pathway. Both GIP and GLP-1 are incretin hormones, meaning they are released from the intestines in response to food intake and play crucial roles in regulating blood glucose levels and appetite.

Dr Morgan Toerien, clinical director at Bodyline Medical Wellness Clinics, is a weight, health, and wellness practitioner at Bodyline and explains how this medication differs from other injectable therapies on the market:

"GLP-1s (glucagon-like-peptide 1) and the GIPs (glucose-dependent insulinotropic polypeptide) are both substances that are naturally found in the body. Their purpose is to regulate appetite and signal to our brains the feeling of being full. When people are struggling with maintaining their weight, one of two things is often happening. Either they're not making enough of these hormones, or their body is resistant to them. That means they might need a higher number of the hormones to get the same effect because what their body is producing is not enough.

What researchers have found is that it might be that they're lacking GIPs. By combining the two hormones, we can treat a broader base of deficiencies. We're not just working on one pathway but working on two pathways.

"Think of it a little bit like trying to fill a paddling pool with one hose or trying to fill it with two hoses. If you've got two different hoses, your chances of getting it filled quicker are better. With tirzepatide, patients can hedge their bets in terms of whichever one of their hormones is more likely to be deficient or more likely to be resistant to, and one will be in the package."

In other words, it is a weight loss injection with an extra mechanism to help users living with obesity successfully lose even more weight. This dual-action approach addresses the fact that obesity is a heterogeneous condition – different people may have different underlying hormonal imbalances contributing to their weight gain. By targeting both pathways simultaneously, tirzepatide offers a broader therapeutic effect that can benefit a wider range of patients.

It has shown incredible results in clinical trials, with one study showing an average weight loss of up to 21% of their starting weight for users over a 72-week period. These results are unprecedented in the field of pharmaceutical weight loss treatment, approaching the levels of weight loss typically only seen with bariatric surgery. However, it's crucial to note that these were results from controlled clinical trials where participants also received lifestyle counselling, dietary guidance, and regular monitoring – components that would need to be replicated in any government scheme for similar results to be achieved.

According to the Medicines and Healthcare products Regulatory Agency (MHRA), Mounjaro is eligible to those with an initial body mass index (BMI) of at least 30 kg/m2, or a BMI of 27 with at least one weight related comorbidity such as heart disease or high blood pressure. This eligibility criteria reflects the evidence base for the medication and ensures it is prescribed to individuals who will benefit most from treatment. It's worth noting that BMI, while useful as a screening tool, has limitations and should be considered alongside other measures of health and body composition.

However, NICE guidelines advise the NHS it must only be prescribed if the patient has a BMI of at least 35 and at least one weight-related comorbidity. This means that on the NHS, patients can only receive this prescription if they are morbidly obese, as opposed to obese. This more restrictive criteria reflects the cost considerations and resource limitations within the NHS, but it also means that many people who could benefit from the medication under MHRA licensing are unable to access it through the NHS. This creates a two-tier system where those who can afford private treatment have access to potentially life-changing medication, while those relying on the NHS must wait until their health has deteriorated to a more severe level.

The medication works by slowing gastric emptying, which helps people feel fuller for longer after eating. It also acts on the brain's appetite centres to reduce hunger signals and food cravings. Additionally, tirzepatide improves insulin sensitivity and helps regulate blood glucose levels, which can be particularly beneficial for individuals with type 2 diabetes or prediabetes. These multiple mechanisms of action contribute to its effectiveness but also mean that the medication requires careful monitoring and dose titration to minimize side effects and optimize results.

At Bodyline, we have been prescribing Mounjaro weight loss injections as part of our comprehensive medical weight loss programmes. Our experience with this medication has shown us that while it is highly effective, success depends heavily on the support structures around the patient. We provide regular consultations with our specialist nurses, nutritional guidance tailored to each individual, strategies for managing side effects, and ongoing monitoring of health markers. This comprehensive approach is what enables our patients to achieve and maintain significant weight loss.

Why just the unemployed?

While unemployment is a huge issue for the UK economy, there's an argument that these game-changing medications should be available based on those who need them rather than based on their socio-economic background. This question strikes at the heart of healthcare ethics and the principles upon which the NHS was founded – that healthcare should be free at the point of use and based on clinical need, not ability to pay or employment status.

This is particularly the case when we consider the number of people already in work and living with obesity, who pay their taxes and contribute to the economy but due to their chronic disease and weight related health problems, are at risk of more sick days. These individuals are actively contributing to society and the economy, yet under the proposed scheme would be excluded from accessing treatment that could improve their health, productivity, and quality of life. This raises questions about fairness and whether we are creating arbitrary distinctions between deserving and undeserving recipients of healthcare.

Obesity increases the risk of life-threatening conditions such as heart disease and cancer, which causes premature deaths within the working population. Even before that, obesity-related health problems contribute to higher rates of absenteeism, resulting in a significant number of lost working days each year. The economic argument for treating obesity in the employed population is arguably stronger than for the unemployed, as the return on investment in terms of reduced sick leave, improved productivity, and extended working lives would be more immediate and measurable.

Just in the UK, 131 million working days are lost annually due to sickness, and obesity reportedly plays a substantial role in these absences. The economic cost of these absences is estimated to be around £22 billion, so logic says if obesity continues to rise, as will that cost. This staggering figure represents lost productivity, reduced tax revenue, and increased burden on social support systems. Addressing obesity in the employed population could have a significant impact on these numbers, potentially delivering economic benefits that far outweigh the cost of treatment.

Excess weight hampers productivity in the workplace, impacting both employers and employees, but additionally the stigma surrounding weight and obesity can lead to discrimination, prejudice, and bullying, which negatively affects the mental health of workers. This creates a vicious cycle where obesity affects mental health, which in turn can lead to further weight gain and reduced ability to engage in healthy behaviours. Breaking this cycle requires comprehensive support that addresses both the physical and psychological aspects of obesity.

It's also important to consider the fact that a person's job or workplace also has an impact on their likelihood of developing obesity. Routines, work environments, and job demands can influence eating habits, activity levels, and overall weight health. Shift workers, for example, face particular challenges due to disrupted circadian rhythms, limited access to healthy food options during night shifts, and difficulty maintaining regular exercise routines. Office workers may face prolonged periods of sitting, easy access to unhealthy snacks, and work cultures that discourage taking breaks for physical activity. Those in high-stress jobs may turn to food as a coping mechanism, while those in physically demanding jobs may lack the energy for additional exercise outside of work.

Consider someone working the night shift – they have limited access to traditional food shopping locations and are forced to buy from fast food locations, the only places that are open. Plus, sleep routine impacts metabolism which increases risk of obesity. Night shift workers have been shown in multiple studies to have higher rates of obesity, diabetes, and cardiovascular disease compared to day workers. This is not a matter of personal choice or willpower, but a consequence of working patterns that disrupt normal physiological functioning. Should these individuals be denied access to effective treatment simply because they are employed?

This article isn't written for the purpose of pitting one section of society against the other for access to weight loss medications – it is just shining a light on the difficulties surrounding this topic. The reality is that obesity affects people across all demographics and employment statuses, and access to treatment should be determined by clinical need and likelihood of benefit, not by arbitrary criteria such as employment status. At Bodyline, we treat patients from all backgrounds, and we know that motivation, commitment, and engagement with treatment are not determined by whether someone is currently employed.

Obesity impacts the economy in several ways, and while getting people back to work is a noble cause, it leaves behind the population that work hard, pay taxes, and live with chronic obesity. Furthermore, it potentially misses an opportunity to prevent people from leaving the workforce in the first place. Early intervention for employed individuals showing signs of obesity-related health problems could prevent the progression to more severe health issues that ultimately lead to unemployment or early retirement. This preventative approach would likely be more cost-effective than waiting until individuals have left the workforce before offering treatment.

There is also a question of whether focusing treatment on unemployed individuals might actually reinforce stigma and discrimination. If the primary justification for providing obesity treatment is to make people "fit for work," this frames obesity primarily as an economic problem rather than a health condition deserving of treatment in its own right. This could further entrench the view that people with obesity are somehow failing in their social obligations, rather than recognizing that they are living with a chronic disease that requires medical intervention.

Medical weight loss treatment and long-term support

At Bodyline, we've been in the business of weight health management and medical weight loss treatments for almost 18 years. That's why we can verifiably say that medical interventions like Mounjaro are not the magic solution to obesity alone. Our extensive experience working with thousands of patients has taught us that while medications like tirzepatide are powerful tools, they are just that – tools that must be used within a broader framework of support, education, and lifestyle modification to achieve lasting results.

In fact, without assured habitual changes in lifestyle and ongoing support throughout the treatment process, as soon as a patient comes off the medication, there is a high chance they will regain the weight they lost in the years following. This phenomenon, known as weight recurrence, is well-documented in the medical literature and represents one of the greatest challenges in obesity treatment. The medications work by altering hormonal signals related to appetite and satiety, but they do not fundamentally change the environmental, behavioural, and psychological factors that contributed to weight gain in the first place.

This is why ongoing counselling, support, and guidance throughout the treatment is crucial to ensure the weight loss is sustainable and works to actually improve their health and overall wellbeing. This is done by incorporating holistic changes to a person's habits and lifestyle that is bespoke to their specific needs. At Bodyline, our programmes include regular consultations with specialist nurses, access to nutritional guidance, support with physical activity planning, strategies for managing emotional eating, and help navigating social situations that may challenge healthy eating habits. This wraparound support is what enables our patients to develop new, sustainable behaviours that support long-term weight maintenance.

There's no use telling someone who works long shifts to go for a run after work when they're already exhausted. This is why our approach is always individualized. We work with each patient to understand their unique circumstances, challenges, and resources, and we develop strategies that are realistic and achievable within their life context. For a shift worker, this might mean focusing on meal preparation strategies, finding opportunities for activity during breaks, or incorporating short bursts of movement throughout the day rather than expecting them to engage in lengthy gym sessions.

With personalised clinical support, like the support we offer within our medical weight loss programmes, life changing weight loss can be sustainable long-term. Even then, if a person is physiologically lacking certain hormones, then coming off medication replacing those hormones will also do them no good, and cause weight to come back. This is an important point that is often overlooked in discussions about weight loss medications. For some individuals, obesity is not simply a result of lifestyle factors but reflects underlying physiological differences in hormone production or hormone sensitivity. For these individuals, long-term or even lifelong medication may be appropriate and necessary, just as insulin is necessary for people with type 1 diabetes.

Offering tirzepatide to get people back to work is not as easy as putting them on 6-month prescriptions and sending them on their way – the support, and maybe even the medication, must be ongoing and holistic, which will be a lot more expensive than the UK government may want to admit. The true cost of an effective weight loss programme includes not just the medication itself, but the healthcare professional time required for consultations and monitoring, the resources needed for nutritional counselling and behavioural support, the systems required to track outcomes and adjust treatment plans, and potentially years of continued treatment for many individuals.

What's more, it is a post-code lottery for access to NHS weight health management support across the country, therefore there isn't even any guarantee that those people with obesity getting treatment on the NHS have the support they require for the medication to properly work! This variation in service provision across different areas of the UK means that even if the government scheme is implemented, its effectiveness may vary dramatically depending on where a person lives. Without investment in building comprehensive weight management services across all areas, simply providing medication is unlikely to deliver the desired outcomes.

The infrastructure required to deliver effective weight loss treatment at scale is substantial. It requires trained healthcare professionals who understand obesity medicine, appointment systems that can accommodate regular follow-ups, access to specialist services for complications or complex cases, and coordination between different healthcare providers. Currently, many areas of the UK lack these services, and NHS weight management programmes often have long waiting lists and limited capacity. Any government scheme would need to address these infrastructure gaps before it could be effectively implemented.

Furthermore, the monitoring required for safe use of these medications is not insignificant. Patients need regular checks of their weight, blood pressure, heart rate, and blood glucose levels. They need to be monitored for side effects, which can include nausea, vomiting, diarrhoea, constipation, and in rare cases more serious complications such as pancreatitis or gallbladder problems. The dose of medication typically needs to be gradually increased over several weeks to minimize side effects, and adjustments may be needed based on individual response and tolerance. All of this requires healthcare professional input and cannot be safely managed through simply dispensing medication without ongoing oversight.

At Bodyline, our patients have access to our clinical team whenever they need support. They can contact us between appointments if they have concerns, and we provide detailed guidance on managing side effects, adjusting diet as weight loss progresses, and troubleshooting any challenges that arise. This level of support is essential for patient safety and treatment success, but it requires significant resources to deliver. Any government scheme would need to ensure similar levels of support are available to all participants.

Obesity in employment: stigma and discrimination

A holistic approach to tackling obesity requires a look at the situation for those living with obesity currently in employment and suffering with the stigma that goes along with them. Weight-based discrimination is pervasive in society and particularly evident in workplace settings, where it can affect every stage of employment from recruitment through to retirement. Understanding and addressing this discrimination is essential if we are serious about supporting people with obesity to participate fully in the workforce.

Since the majority of the public see the answer to excess weight problems to be "eat less, move more", there's an underlying assumption that those living with obesity are eating too much and not moving enough. This oversimplification of obesity ignores the complex interplay of genetic, environmental, psychological, and physiological factors that contribute to weight gain and make weight loss challenging. It places the blame squarely on the individual and frames obesity as a personal failing rather than a chronic disease requiring medical intervention.

That means that the public perception of obesity is that it is a result of over-consumption and laziness. While for some people this may be partially true, obesity is in fact much more complex than that, and can be impacted by a wide variety of factors out of our control such as genetics, ethnicity, and medical history. Research has identified numerous genetic variants that influence body weight, metabolic rate, and fat distribution. Certain medications, including some antidepressants, antipsychotics, and steroids, can cause weight gain. Medical conditions such as hypothyroidism, polycystic ovary syndrome, and Cushing's syndrome can contribute to obesity. Socioeconomic factors, including food insecurity, lack of access to safe spaces for physical activity, and work demands, all play a role.

However, since the wider public is not informed about these factors, people with obesity face a stigma daily, and many times see discrimination in the workplace and throughout society. This stigma can be explicit, such as derogatory comments or exclusion from social activities, or implicit, such as assumptions about a person's capabilities, work ethic, or professionalism based on their weight. The psychological impact of this stigma is significant and can lead to anxiety, depression, low self-esteem, and social isolation, all of which can further complicate weight management efforts.

In employment specifically, studies show that people with obesity see discrimination at every stage of their work, from recruitment to salaries to promotions or dismissals. Research has shown that job applicants with obesity are less likely to be called for interview, even when their qualifications are identical to those of candidates without obesity. When employed, individuals with obesity may receive lower starting salaries, be passed over for promotions, be subjected to more scrutiny of their performance, and face higher rates of disciplinary action. In some cases, weight has been cited as a reason for dismissal, particularly in roles where appearance is considered important.

It's one thing to offer weight loss medications to those out of work, but if we don't fix the way we see obesity in work and in the wider society, potential new employees will continue to face the stigma of obesity. Even if the government scheme successfully helps unemployed individuals lose weight and return to work, they may still face discrimination and bias in the workplace. Without addressing the underlying attitudes and systemic discrimination, we risk simply cycling people through a system where they lose weight to gain employment, face discrimination that affects their mental health and job security, potentially regain weight due to stress and lack of ongoing support, and find themselves unemployed again.

But if obesity is viewed as the chronic disease that it is, then perhaps employers will see it as something they can include in their corporate health packages offered by Bodyline to retain their employees and maintain productivity. There is growing recognition among forward-thinking employers that supporting employee health, including weight management, is good for business. Healthy employees take fewer sick days, are more productive, have higher morale, and are more likely to remain with the company long-term. Investing in comprehensive health and wellbeing programmes that include access to weight management support can deliver significant returns on investment.

This would save taxpayer money, put the onus on employers to better protect their employees from developing obesity (particularly if the career lifestyle is linked to weight gain), and potentially remove the stigma and its subsequent discrimination from the workplace. Employer-sponsored health programmes can also address the workplace factors that contribute to obesity, such as providing healthier food options in canteens, creating opportunities for physical activity during the workday, and fostering a culture that values health and wellbeing. This preventative approach could reduce the number of people developing obesity in the first place, which is ultimately more effective than waiting to treat obesity after it has developed.

At Bodyline, we work with employers through our corporate health programmes to provide weight management support as part of comprehensive employee wellness initiatives. We have seen how this approach benefits both employees and employers, creating healthier, more engaged workforces while demonstrating that the organization values its employees' wellbeing. This model could be expanded more broadly if there was policy support and recognition that workplace health interventions are a valuable investment in workforce sustainability.

In conclusion: What is the 'why' for weight loss jabs?

While public health policy isn't something we have much weight in, from the perspective of our experienced staff and clinical team we know the complexities of medical weight loss programmes and what makes them work. Our nearly two decades of experience, working with over 100,000 patients across the UK, has given us deep insights into what drives successful, sustainable weight loss and what factors lead to treatment failure or weight recurrence.

What we have found over the years is that those who have come away with success and transformed their lives the most are those people who have goals that go beyond slimming down for a dress or going on holiday. While these short-term goals can provide initial motivation, they are rarely sufficient to sustain the long-term commitment required for lasting weight loss. The patients who achieve and maintain significant weight loss are those who have connected their weight loss goals to deeper values and life objectives.

The people who lose weight and sustain that weight loss are considering their health, their future, their ability to play with their children without getting out of breath, the joy of movement again, or overcoming chronic pain. They are motivated by the desire to reduce their medication burden, to avoid the health complications they have seen in family members, to be present for important life events, or to reclaim activities and experiences that obesity has taken from them. These intrinsic motivations are powerful and enduring in a way that external motivations like employment often are not.

Perhaps we should be reframing the conversation back to the personal reasons for choosing medically supported weight loss will work much better than further stigmatizing those who live with obesity and may be unemployed. By framing obesity treatment primarily as a means to employment, we risk sending the message that people with obesity are only valuable insofar as they can contribute economically. This is not only ethically problematic but also potentially counterproductive, as it may undermine the intrinsic motivation that is so important for long-term success.

Medical weight loss treatments only work when there is a sustained effort from the patient to change their lives through habit forming and lifestyle alterations, and ongoing support from clinicians is what can ensure this is done safely and effectively – and in a way that is bespoke to their circumstances. This is true regardless of whether the patient is employed or unemployed. The factors that predict success in weight loss treatment are not related to employment status but rather to factors such as readiness for change, social support, mental health, and access to resources and support services.

If the government is serious about using weight loss medications to improve public health and economic productivity, the focus should be on building comprehensive, accessible weight management services that are available to all who need them based on clinical criteria. These services should include not just medication but also nutritional counselling, psychological support, physical activity guidance, and long-term follow-up. They should be delivered by trained professionals who understand obesity as a complex, chronic disease. And they should be adequately funded not just for the initial treatment period but for the ongoing support that many patients will need.

Furthermore, any initiative focused on obesity and employment should also address the workplace factors that contribute to obesity and the discrimination that people with obesity face in employment settings. This means working with employers to create healthier work environments, implementing and enforcing anti-discrimination policies, and educating the public about the complex nature of obesity. Without these broader changes, simply providing medication to unemployed individuals is unlikely to achieve the desired outcomes and may even perpetuate harmful stigma.

At Bodyline, we remain committed to providing high-quality, comprehensive weight management support to all who need it, regardless of their employment status. We believe that access to effective obesity treatment should be based on clinical need and that all individuals living with obesity deserve support, respect, and evidence-based care. We hope that as the conversation around obesity, employment, and access to treatment continues, these principles will be at the forefront of policy development.

Contact Bodyline today to find out more about our safe and effective weight loss programmes and range of treatment options.

If you are considering medical weight loss treatment, whether you are currently employed or unemployed, we encourage you to book a consultation with our specialist team. We can assess your individual circumstances, discuss the treatment options available, and develop a personalised plan that addresses your unique needs and goals. Our programmes include access to the latest weight loss medications including Mounjaro and Wegovy, as well as comprehensive support from our experienced clinical team. We have clinics located across the Northwest of England, and we also offer remote consultations for patients across the UK.

Corporate weight health

Did you know that by partnering with specialist weight health providers such as Bodyline, employers can offer the latest in medical weight loss solutions alongside fully supported weight loss programmes for their employees? In the current discussion around obesity and employment, forward-thinking employers have an opportunity to take a proactive approach by investing in the health of their workforce before productivity and attendance issues arise.

This approach ensures that employees can receive personalised treatment options tailored to their needs, prioritizing medically targeted solutions for those who struggle to lose weight with diet and exercise alone. Our corporate programmes can be delivered on-site at your workplace or through our network of clinics, making it convenient for employees to access care without taking significant time away from work. We provide confidential, professional services that respect employee privacy whilst delivering measurable improvements in health outcomes.

The benefits of corporate weight health programmes extend beyond individual employee health. Employers who invest in comprehensive wellness programmes often see reduced absenteeism, improved productivity, enhanced employee morale and engagement, lower healthcare costs, and improved retention rates. In an increasingly competitive labour market, offering robust health and wellbeing support can also be a valuable tool for attracting top talent. Employees increasingly expect their employers to support their health and wellbeing, and comprehensive programmes that include weight management support demonstrate a genuine commitment to employee welfare.

Workplace weight management support should start with listening to employees and understanding what would help them. Any programme should be voluntary, confidential and centred on individual health goals, with clear information about what is available and how to access it.

For employers, this means creating space for staff to seek support without assumptions about their health, abilities or motivation. Access to treatment should sit alongside practical steps to make the workplace more inclusive and address weight-based stigma.

Putting Health at the Centre of the Conversation

At Bodyline Clinic, we believe that conversations about obesity and employment should keep the individual’s wellbeing at their heart. People deserve respectful care and the opportunity to explore treatment based on their clinical needs, whatever their employment circumstances.

If you are an employer exploring weight management support for your workforce, contact Bodyline Clinic to discuss the available options. If you are seeking help for yourself, our clinical team can assess your suitability for treatment and talk through your goals.